Home    Back

Trametinib    (DrugBank: Trametinib)

3 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1
34Neurofibromatosis7
279Huge venous malformation with cervical, oral and pharyngeal diffuse lesion1

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04326283
(ClinicalTrials.gov)		April 2, 202024/3/2020Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)A Sequential Dose-Escalation, Randomized, Active-Controlled, Multi-Center, Phase 1/2a Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of SNR1611 in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: Trametinib (0.5 mg);Drug: Trametinib (1 mg);Drug: Trametinib (2 mg);Drug: Riluzole (100 mg)Genuv Inc.NULLRecruiting19 Years75 YearsAll30Phase 1;Phase 2Korea, Republic of

34. Neurofibromatosis    [ 120 clinical trials,   182 drugs,   (DrugBank: 72 drugs),   84 drug target genes,   194 drug target pathways]
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 120 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04201457
(ClinicalTrials.gov)		November 20, 201912/12/2019A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF AberrationPhase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young AdultsLow Grade Glioma (LGG) of Brain With BRAF Aberration;High Grade Glioma (HGG) of the Brain With BRAF Aberration;Low Grade Glioma of Brain With Neurofibromatosis Type 1Drug: Dabrafenib;Drug: Trametinib;Drug: HydroxychloroquinePediatric Brain Tumor ConsortiumNULLRecruiting1 Year30 YearsAll75Phase 1;Phase 2United States
2NCT03975829
(ClinicalTrials.gov)		November 4, 201930/5/2019Pediatric Long-Term Follow-up and Rollover StudyAn Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)Diffuse Astrocytoma;Anaplastic Astrocytoma;Astrocytoma;Oligodendroglioma, Childhood;Anaplastic Oligodendroglioma;Glioblastoma;Pilocytic Astrocytoma;Giant Cell Astrocytoma;Pleomorphic Xanthoastrocytoma;Anaplastic Pleomorphic Xanthoastrocytoma;Angiocentric Glioma;Chordoid Glioma of Third Ventricle;Gangliocytoma;Ganglioglioma;Anaplastic Ganglioglioma;Dysplastic Gangliocytoma of Cerebrellum;Desmoplastic Infantile Astrocytoma and Ganglioglioma;Papillary Glioneuronal Tumor;Rosette-forming Glioneurona Tumor;Central Neurocytoma;Extraventricular Neurocytoma;Cerebellar Liponeurocytoma;Neurofibromatosis Type 1Drug: dabrafenib;Drug: trametinibNovartis PharmaceuticalsNULLRecruiting1 YearN/AAll250Phase 4United States;France;Spain;United Kingdom
3EUCTR2019-001317-16-NL
(EUCTR)		30/10/201916/10/2019The TRAIN study: TRAmetinib In Neurofibromatosis type 1 related symptomatic plexiform neurofibromas The TRAIN study: TRAmetinib In Neurofibromatosis type 1 related symptomatic plexiform neurofibromas - TRAIN study: Trametinib in NF1-PNF Adult patients (age >17 years) with (mosaic) NF1 with inoperable symptomatic plexiform neurofibromas
MedDRA version: 20.0;Level: PT;Classification code 10029267;Term: Neurofibroma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA version: 20.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		ErasmusMCNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		30Phase 2Netherlands
4NCT03741101
(ClinicalTrials.gov)		June 10, 20195/11/2018Treatment of NF1-related Plexiform Neurofibroma With TrametinibTreatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain ReliefNeurofibromatosis 1;Child;Neurofibroma, PlexiformDrug: TrametinibRegion SkaneNovartisRecruiting1 Year17 YearsAll15Phase 2Sweden
5EUCTR2018-001846-32-SE
(EUCTR)		18/09/201831/07/2018Treatment of symptomatic plexiform neurofibromas, a benign tumour associated with the disorder Neurofibromatosis type 1, in children with the drug trametinibTreatment of NF1-related plexiform neurofibroma with trametinib; a single arm, open-label trial with the goals of volumetric partial remission and pain relief - plexifpc NF1-related plexiform neurofibroma;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: Mekinist
Product Name: Mekinist		VO Barnmedicin, Skånes University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		15Phase 2Sweden
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT03232892
(ClinicalTrials.gov)		February 13, 201814/7/2017Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung CancerPhase II Trial to Evaluate Trametinib in Patients With Advanced NF1-mutant Non-small Cell Lung CancerNon-small Cell Lung CancerDrug: TrametinibUniversity of California, San FranciscoNovartis Pharmaceuticals;American Cancer Society, Inc.Terminated18 YearsN/AAll1Phase 2United States
7NCT03190915
(ClinicalTrials.gov)		October 6, 201716/6/2017Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic LeukemiaA Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic LeukemiaJuvenile Myelomonocytic Leukemia;Neurofibromatosis Type 1Drug: TrametinibNational Cancer Institute (NCI)Children's Oncology GroupRecruiting1 Month21 YearsAll24Phase 2United States

Back to top


279. Huge venous malformation with cervical, oral and pharyngeal diffuse lesion    [ 12 clinical trials,   23 drugs,   (DrugBank: 9 drugs),   3 drug target genes,   103 drug target pathways]
Searched query = "Huge venous malformation with cervical, oral and pharyngeal diffuse lesion", "Huge venous malformation", "Venous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 12 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04258046
(ClinicalTrials.gov)		March 31, 202016/1/2020Trametinib in the Treatment of Complicated Extracranial Arterial Venous MalformationPhase II Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation (VM)Venous Malformation;Arterial DiseaseDrug: Trametinib tabletStanford UniversityBoston Children's HospitalNot yet recruiting12 Years60 YearsAll30Phase 2United States

Back to top